Geoffrey Beran Rose sold $27k of LUNG
CHIEF COMMERCIAL OFFICER at Pulmonx Corp. 4,376 shares at an average of $6.18, traded Dec 2, 2024, filed Dec 4, 2024.
Score components
- +15RoleOfficer
- +5Trade size$27k at market
- 0Share of holdings soldSold 1.5% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.4%, 3m +25.5%, 6m -52.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028319, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | SOpen-market sale Common Stock | -392 | $6.19 | $2,426 | 295,041 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock | -690 | $6.18 | $4,264 | 294,351 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock | -1,756 | $6.19 | $11k | 292,595 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock | -1,538 | $6.18 | $9,505 | 291,057 | Dec 4, 2024 |
Related signals
Other insiders at Pulmonx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $95k 41,882 shares | -4% | |
| 35Weak | Pulmonx Corp | David Aaron Lehman General Counsel | $32k 14,334 shares | -4% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose Chief Commercial Officer | $18k 7,879 shares | -2% | |
| 35Weak | Pulmonx Corp | Srikanth Radhakrishnan Chief Science & Techn. Officer | $32k 14,245 shares | -4% | |
| 50Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $97k 67,813 shares | -5% | |
| 30Weak | Pulmonx Corp | David Aaron Lehman GENERAL COUNSEL | $17k 12,237 shares | -5% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | $11k 7,732 shares | -2% | |
| 30Weak | Pulmonx Corp | Srikanth Radhakrishnan Chief Science &Techn. Officer | $15k 10,483 shares | -6% | |
| 21Weak | Pulmonx Corp | Daniel P Florin director | $46k 23,321 shares | -20% | |
| 40Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $14k 8,805 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.